Biolase Inc Revenue Growth Rates (BIOL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Biolase Inc   (BIOL)
 

BIOL's Revenue Growth by Quarter and Year

Biolase Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BIOL Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September 10.38
2nd Quarter June 10.61
1st Quarter March 9.34
FY 30.33

BIOLs Annual Revenue
Biolase Inc 's Revenue in the fiscal year 2023 $ 48.72 millions
Biolase Inc 's Revenue in the fiscal year 2022 $ 48.46 millions
Biolase Inc 's Revenue in the fiscal year 2021 $ 39.19 millions
Biolase Inc 's Revenue in the fiscal year 2020 $ 22.78 millions
Biolase Inc 's Revenue in the fiscal year 2019 $ 37.80 millions




BIOL Revenue third quarter 2024 Y/Y Growth Comment
Biolase Inc reported decrease in Revenue in the third quarter 2024 by -3.42% to $ 10.38 millions, from the same quarter in 2023.
The decrease in the third quarter 2024 Biolase Inc 's Revenue compares unfavorably to the Company's average Revenue growth of 3.11%.

Looking into third quarter 2024 results within Medical Equipment & Supplies industry 136 other companies have achieved higher Revenue growth. While Biolase Inc ' s Revenue decline of -3.42% ranks overall at the positon no. 2616 in the third quarter 2024.


BIOL Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - -4.7 % 13.22 % 45.66 %
3rd Quarter September -3.42 % -10.49 % 26.02 % 45.72 %
2nd Quarter June -24.86 % 15.36 % 34.06 % 210.54 %
1st Quarter March -10.79 % 2.95 % 25.25 % 69.87 %
FY   - 0.54 % 23.68 % -

Financial Statements
Biolase Inc 's third quarter 2024 Revenue $ 10.38 millions BIOL's Income Statement
Biolase Inc 's third quarter 2023 Revenue $ 10.75 millions Quarterly BIOL's Income Statement


BIOL Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 24.56 % 16.99 % 30.22 %
3rd Quarter September -2.15 % -23.87 % -1.88 % 4.38 %
2nd Quarter June 13.6 % 34.86 % 20.35 % 12.44 %
1st Quarter March -30.25 % -25.48 % -18.05 % -4.69 %
FY (Year on Year)   - 0.54 % 23.68 % -


Back to BIOL Growth rate Comparisons >> Back to BIOL Growth rate Comparisons >>


Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #137
Healthcare Sector #428
Overall #2616

Revenue Y/Y Growth Statistics
High Average Low
210.89 % 3.11 % -66.02 %
(Dec 31 2021)   (Sep 30 2020)
Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #137
Healthcare Sector #428
Overall #2616
Revenue Y/Y Growth Statistics
High Average Low
210.89 % 3.11 % -66.02 %
(Dec 31 2021)   (Sep 30 2020)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Biolase Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
122.57 % 2.89 % -53.02 %
(Sep 30 2020)  


BIOL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2024 Biolase Inc disclosed fall in Revenue from the second quarter by -2.15% to $ 10.38 millions, from $ 10.61 millions achived in the previous reporting period.

But that's not important problem, as Biolase Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 129 other companies have achieved higher Revenue quarter on quarter growth. While Biolase Inc 's Revenue growth quarter on quarter, overall rank is 2682.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #130
Healthcare Sector #421
Overall #2682
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #130
Healthcare Sector #421
Overall #2682
Revenue Q/Q Growth Statistics
High Average Low
122.57 % 2.89 % -53.02 %
(Sep 30 2020)  


BIOL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2024 Biolase Inc disclosed fall in Revenue from the second quarter by -2.15% to $ 10.38 millions, from $ 10.61 millions achived in the previous reporting period.

But that's not important problem, as Biolase Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 129 other companies have achieved higher Revenue quarter on quarter growth. While Biolase Inc 's Revenue growth quarter on quarter, overall rank is 2682.


Biolase Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)
Cumulative Revenue 12 Months Ending $ 43.72 $ 44.08 $ 47.59 $ 48.72 $ 49.38
Y / Y Revenue Growth (TTM) -11.47 % -12.96 % -2.4 % 0.54 % 5.48 %
Year on Year Revenue Growth Overall Ranking # 1476 # 852 # 0 # 0 # 559
Seqeuential Revenue Change (TTM) -0.83 % -7.37 % -2.32 % -1.33 % -2.5 %
Seq. Revenue Growth (TTM) Overall Ranking # 2285 # 1565 # 0 # 0 # 1759


Cumulative Revenue growth Comment
Biolase Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2024. If the fiscal year would end in Sep 30 2024, Biolase Inc 's annual Revenue decline would be -11.47% year on year to $44 millions.

In the Healthcare sector 283 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 852 to 1476.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 121
Healthcare Sector # 284
Overall # 1476

Revenue TTM Y/Y Growth Statistics
High Average Low
72.03 %
 0.27 %
-39.89 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 370
S&P 500 # 2285
Cumulative Revenue growth Comment
Biolase Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2024. If the fiscal year would end in Sep 30 2024, Biolase Inc 's annual Revenue drop would be -11.47% year on year to $44 millions.

In the Healthcare sector 283 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 852 to 1476.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 121
Healthcare Sector # 284
Overall # 1476

Revenue TTM Y/Y Growth Statistics
High Average Low
72.03 %
0.27 %
-39.89 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 370
S&P 500 # 2285




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BIOL's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2024
West Pharmaceutical Services Inc -0.08%$ -0.080 millions
Nektar Therapeutics-0.08%$ -0.083 millions
Apyx Medical Corp-0.22%$ -0.219 millions
Avantor Inc -0.34%$ -0.337 millions
Avanos Medical Inc -0.35%$ -0.352 millions
Integra Lifesciences Holdings Corp-0.41%$ -0.415 millions
Nuwellis Inc -0.59%$ -0.588 millions
Alkermes Plc -0.73%$ -0.734 millions
Prestige Consumer Healthcare Inc -0.92%$ -0.922 millions
Psychemedics Corporation-1.02%$ -1.021 millions
Petros Pharmaceuticals inc -1.34%$ -1.342 millions
10x Genomics Inc -1.39%$ -1.391 millions
Abcellera Biologics Inc -1.39%$ -1.394 millions
Nephros Inc -1.41%$ -1.409 millions
Charles River Laboratories International inc -1.64%$ -1.642 millions
Inspiremd Inc -1.67%$ -1.669 millions
Cv Sciences Inc -1.69%$ -1.691 millions
Elutia Inc -1.71%$ -1.712 millions
Enhabit Inc -1.82%$ -1.820 millions
Accuray Incorporated-1.96%$ -1.956 millions
Zimvie Inc -1.98%$ -1.984 millions
Reflect Scientific Inc-2.25%$ -2.254 millions
Upstream Bio Inc -2.25%$ -2.254 millions
Maravai Lifesciences Holdings Inc -2.49%$ -2.490 millions
Biogen Inc -2.55%$ -2.549 millions
Fresenius Medical Care Ag-2.66%$ -2.658 millions
Opko Health Inc -2.78%$ -2.779 millions
Precision Optics Corporation Inc -2.87%$ -2.874 millions
Msa Safety Inc-2.98%$ -2.985 millions
Teladoc Health Inc -2.99%$ -2.988 millions


About Biolase Inc Revenue Growth Rates (BIOL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Biolase Inc (CIK 811240).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-24-123472
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Biolase Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.